530 related articles for article (PubMed ID: 31587793)
41. Cardiomyopathy associated with cancer therapy.
Yu AF; Steingart RM; Fuster V
J Card Fail; 2014 Nov; 20(11):841-52. PubMed ID: 25151211
[TBL] [Abstract][Full Text] [Related]
42. The Future of Onco-Cardiology: We Are Not Just "Side Effect Hunters".
Abe J; Martin JF; Yeh ET
Circ Res; 2016 Sep; 119(8):896-9. PubMed ID: 27688305
[TBL] [Abstract][Full Text] [Related]
43. Cardio-oncology Related to Heart Failure: Pediatric Considerations for Cardiac Dysfunction.
Rose-Felker K; Border WL; Hong BJ; Chow EJ
Heart Fail Clin; 2017 Apr; 13(2):311-325. PubMed ID: 28279417
[TBL] [Abstract][Full Text] [Related]
44. Clinical Practice and Research in Cardio-Oncology: Finding the "Rosetta Stone" for Establishing Program Excellence in Cardio-oncology.
Adusumalli S; Alvarez-Cardona J; Khatana SM; Mitchell JD; Blaes AH; Casselli SJ; O'Quinn R; Lenihan DJ
J Cardiovasc Transl Res; 2020 Jun; 13(3):495-505. PubMed ID: 32444945
[TBL] [Abstract][Full Text] [Related]
45. Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.
Moudgil R; Yeh ET
Can J Cardiol; 2016 Jul; 32(7):863-870.e5. PubMed ID: 27117975
[TBL] [Abstract][Full Text] [Related]
46. Electrocardiographic abnormalities and mortality in aging survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study.
Mulrooney DA; Soliman EZ; Ehrhardt MJ; Lu L; Duprez DA; Luepker RV; Armstrong GT; Joshi VM; Green DM; Srivastava D; Krasin MJ; Morris GS; Robison LL; Hudson MM; Ness KK
Am Heart J; 2017 Jul; 189():19-27. PubMed ID: 28625376
[TBL] [Abstract][Full Text] [Related]
47. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers.
Chen MH; Colan SD; Diller L
Circ Res; 2011 Mar; 108(5):619-28. PubMed ID: 21372293
[TBL] [Abstract][Full Text] [Related]
48. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Spallarossa P; Maurea N; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1(Suppl 1):S84-92. PubMed ID: 27183529
[TBL] [Abstract][Full Text] [Related]
49. Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome.
Tilemann LM; Heckmann MB; Katus HA; Lehmann LH; Müller OJ
Clin Res Cardiol; 2018 Apr; 107(4):271-280. PubMed ID: 29453595
[TBL] [Abstract][Full Text] [Related]
50. Chemotherapy-related cardiotoxicity: are Australian practitioners missing the point?
Conyers R; Costello B; La Gerche A; Tripaydonis A; Burns C; Ludlow L; Lange P; Ekert P; Mechinaud F; Cheung M; Martin M; Elliot D
Intern Med J; 2017 Oct; 47(10):1166-1172. PubMed ID: 28485067
[TBL] [Abstract][Full Text] [Related]
51. Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity.
Shelburne N; Simonds NI; Adhikari B; Alley M; Desvigne-Nickens P; Dimond E; Filipski K; Gallicchio L; Minasian L
Curr Oncol Rep; 2019 Jan; 21(1):9. PubMed ID: 30701318
[TBL] [Abstract][Full Text] [Related]
52. Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.
Sayed N; Ameen M; Wu JC
Cardiovasc Res; 2019 Apr; 115(5):949-959. PubMed ID: 30768178
[TBL] [Abstract][Full Text] [Related]
53. Perioperative Cardiothoracic and Vascular Risk in Childhood Cancer and its Survivors.
Ketterl TG; Latham GJ
J Cardiothorac Vasc Anesth; 2021 Jan; 35(1):162-175. PubMed ID: 32360009
[TBL] [Abstract][Full Text] [Related]
54. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
55. Cardio-oncology: management of cardiovascular toxicity.
Markman TM; Markman M
F1000Res; 2019; 8():. PubMed ID: 30755794
[TBL] [Abstract][Full Text] [Related]
56. Echocardiography and Cardio-Oncology.
Negishi T; Miyazaki S; Negishi K
Heart Lung Circ; 2019 Sep; 28(9):1331-1338. PubMed ID: 31230869
[TBL] [Abstract][Full Text] [Related]
57. [How to organise cardiovascular management of cancer patients?].
Thuny F; Cautela J
Rev Prat; 2018 Mar; 68(3):332-335. PubMed ID: 30869302
[TBL] [Abstract][Full Text] [Related]
58. Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology.
Muhandiramge J; Zalcberg JR; van Londen GJ; Warner ET; Carr PR; Haydon A; Orchard SG
Curr Oncol Rep; 2022 Nov; 24(11):1579-1592. PubMed ID: 35796941
[TBL] [Abstract][Full Text] [Related]
59. Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies - part 1.
Manolis AA; Manolis TA; Mikhailidis DP; Manolis AS
Expert Opin Drug Saf; 2018 Sep; 17(9):875-892. PubMed ID: 30126304
[TBL] [Abstract][Full Text] [Related]
60. The Role of Imaging with Cardiac Computed Tomography in Cardio-Oncology Patients.
Pitekova B; Ravi S; Shah SV; Mladosievicova B; Heitner S; Ferencik M
Curr Cardiol Rep; 2016 Sep; 18(9):87. PubMed ID: 27443383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
